

Global Primary Biliary Cirrhosis Drug Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

https://marketpublishers.com/r/G94E68129628EN.html

Date: July 2022

Pages: 100

Price: US\$ 3,480.00 (Single User License)

ID: G94E68129628EN

Abstracts

The Primary Biliary Cirrhosis Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Primary Biliary Cirrhosis Drug market size is estimated to be worth US\$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Clinic accounting for % of the Primary Biliary Cirrhosis Drug global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Budesonide segment is altered to a % CAGR between 2022 and 2028.

Global key manufacturers of Primary Biliary Cirrhosis Drug include AlbireoPharma, CymaBay Therapeutics, Inc., Dr. Falk Pharma GmbH, Enanta Pharmaceuticals, Inc., and GlaxoSmithKline Plc, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Primary Biliary Cirrhosis Drug market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.



Market segment by Type, covers	
Budesonide	
FFP-104	
GSK-2330672	
MBX-8025	
NGM-282	
Others	
Market segment by Application can be divided into	
Clinic	
Hospital	
Others	
The key market players for global Primary Biliary Cirrhosis Drug market are listed below:	
AlbireoPharma	
CymaBay Therapeutics, Inc.	
Dr. Falk Pharma GmbH	
Enanta Pharmaceuticals, Inc.	
GlaxoSmithKline Plc	
Intercept Pharmaceuticals, Inc.	



Johnson & Johnson

MediGene AG

NGM Biopharmaceuticals, Inc.

Virobay Inc.

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Primary Biliary Cirrhosis Drug product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Primary Biliary Cirrhosis Drug, with price, sales, revenue and global market share of Primary Biliary Cirrhosis Drug from 2019 to 2022.

Chapter 3, the Primary Biliary Cirrhosis Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Primary Biliary Cirrhosis Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.



Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Primary Biliary Cirrhosis Drug market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Primary Biliary Cirrhosis Drug.

Chapter 13, 14, and 15, to describe Primary Biliary Cirrhosis Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.



Contents

1 MARKET OVERVIEW

- 1.1 Primary Biliary Cirrhosis Drug Introduction
- 1.2 Market Analysis by Type
- 1.2.1 Overview: Global Primary Biliary Cirrhosis Drug Revenue by Type: 2017 Versus
- 2021 Versus 2028
 - 1.2.2 Budesonide
 - 1.2.3 FFP-104
 - 1.2.4 GSK-2330672
 - 1.2.5 MBX-8025
 - 1.2.6 NGM-282
 - 1.2.7 Others
- 1.3 Market Analysis by Application
 - 1.3.1 Overview: Global Primary Biliary Cirrhosis Drug Revenue by Application: 2017

Versus 2021 Versus 2028

- 1.3.2 Clinic
- 1.3.3 Hospital
- 1.3.4 Others
- 1.4 Global Primary Biliary Cirrhosis Drug Market Size & Forecast
 - 1.4.1 Global Primary Biliary Cirrhosis Drug Sales in Value (2017 & 2021 & 2028)
 - 1.4.2 Global Primary Biliary Cirrhosis Drug Sales in Volume (2017-2028)
 - 1.4.3 Global Primary Biliary Cirrhosis Drug Price (2017-2028)
- 1.5 Global Primary Biliary Cirrhosis Drug Production Capacity Analysis
 - 1.5.1 Global Primary Biliary Cirrhosis Drug Total Production Capacity (2017-2028)
 - 1.5.2 Global Primary Biliary Cirrhosis Drug Production Capacity by Geographic Region
- 1.6 Market Drivers, Restraints and Trends
 - 1.6.1 Primary Biliary Cirrhosis Drug Market Drivers
 - 1.6.2 Primary Biliary Cirrhosis Drug Market Restraints
 - 1.6.3 Primary Biliary Cirrhosis Drug Trends Analysis

2 MANUFACTURERS PROFILES

- 2.1 AlbireoPharma
 - 2.1.1 AlbireoPharma Details
 - 2.1.2 AlbireoPharma Major Business
 - 2.1.3 AlbireoPharma Primary Biliary Cirrhosis Drug Product and Services
 - 2.1.4 AlbireoPharma Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross



Margin and Market Share (2019, 2020, 2021, and 2022)

- 2.2 CymaBay Therapeutics, Inc.
 - 2.2.1 CymaBay Therapeutics, Inc. Details
 - 2.2.2 CymaBay Therapeutics, Inc. Major Business
 - 2.2.3 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product and Services
 - 2.2.4 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales, Price,

Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

- 2.3 Dr. Falk Pharma GmbH
 - 2.3.1 Dr. Falk Pharma GmbH Details
 - 2.3.2 Dr. Falk Pharma GmbH Major Business
 - 2.3.3 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product and Services
- 2.3.4 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales, Price, Revenue,

Gross Margin and Market Share (2019, 2020, 2021, and 2022)

- 2.4 Enanta Pharmaceuticals, Inc.
 - 2.4.1 Enanta Pharmaceuticals, Inc. Details
 - 2.4.2 Enanta Pharmaceuticals, Inc. Major Business
- 2.4.3 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product and Services
- 2.4.4 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
- 2.5 GlaxoSmithKline Plc
 - 2.5.1 GlaxoSmithKline Plc Details
 - 2.5.2 GlaxoSmithKline Plc Major Business
 - 2.5.3 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product and Services
- 2.5.4 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
- 2.6 Intercept Pharmaceuticals, Inc.
 - 2.6.1 Intercept Pharmaceuticals, Inc. Details
 - 2.6.2 Intercept Pharmaceuticals, Inc. Major Business
- 2.6.3 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product and Services
- 2.6.4 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
- 2.7 Johnson & Johnson
 - 2.7.1 Johnson & Johnson Details
 - 2.7.2 Johnson & Johnson Major Business
 - 2.7.3 Johnson & Johnson Primary Biliary Cirrhosis Drug Product and Services
- 2.7.4 Johnson & Johnson Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)



- 2.8 MediGene AG
 - 2.8.1 MediGene AG Details
 - 2.8.2 MediGene AG Major Business
- 2.8.3 MediGene AG Primary Biliary Cirrhosis Drug Product and Services
- 2.8.4 MediGene AG Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
- 2.9 NGM Biopharmaceuticals, Inc.
 - 2.9.1 NGM Biopharmaceuticals, Inc. Details
 - 2.9.2 NGM Biopharmaceuticals, Inc. Major Business
- 2.9.3 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product and Services
- 2.9.4 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.10 Virobay Inc.
 - 2.10.1 Virobay Inc. Details
 - 2.10.2 Virobay Inc. Major Business
- 2.10.3 Virobay Inc. Primary Biliary Cirrhosis Drug Product and Services
- 2.10.4 Virobay Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

3 PRIMARY BILIARY CIRRHOSIS DRUG BREAKDOWN DATA BY MANUFACTURER

- 3.1 Global Primary Biliary Cirrhosis Drug Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
- 3.2 Global Primary Biliary Cirrhosis Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022)
- 3.3 Key Manufacturer Market Position in Primary Biliary Cirrhosis Drug
- 3.4 Market Concentration Rate
- 3.4.1 Top 3 Primary Biliary Cirrhosis Drug Manufacturer Market Share in 2021
- 3.4.2 Top 6 Primary Biliary Cirrhosis Drug Manufacturer Market Share in 2021
- 3.5 Global Primary Biliary Cirrhosis Drug Production Capacity by Company: 2021 VS 2022
- 3.6 Manufacturer by Geography: Head Office and Primary Biliary Cirrhosis Drug Production Site
- 3.7 New Entrant and Capacity Expansion Plans
- 3.8 Mergers & Acquisitions

4 MARKET ANALYSIS BY REGION



- 4.1 Global Primary Biliary Cirrhosis Drug Market Size by Region
 - 4.1.1 Global Primary Biliary Cirrhosis Drug Sales in Volume by Region (2017-2028)
 - 4.1.2 Global Primary Biliary Cirrhosis Drug Revenue by Region (2017-2028)
- 4.2 North America Primary Biliary Cirrhosis Drug Revenue (2017-2028)
- 4.3 Europe Primary Biliary Cirrhosis Drug Revenue (2017-2028)
- 4.4 Asia-Pacific Primary Biliary Cirrhosis Drug Revenue (2017-2028)
- 4.5 South America Primary Biliary Cirrhosis Drug Revenue (2017-2028)
- 4.6 Middle East and Africa Primary Biliary Cirrhosis Drug Revenue (2017-2028)

5 MARKET SEGMENT BY TYPE

- 5.1 Global Primary Biliary Cirrhosis Drug Sales in Volume by Type (2017-2028)
- 5.2 Global Primary Biliary Cirrhosis Drug Revenue by Type (2017-2028)
- 5.3 Global Primary Biliary Cirrhosis Drug Price by Type (2017-2028)

6 MARKET SEGMENT BY APPLICATION

- 6.1 Global Primary Biliary Cirrhosis Drug Sales in Volume by Application (2017-2028)
- 6.2 Global Primary Biliary Cirrhosis Drug Revenue by Application (2017-2028)
- 6.3 Global Primary Biliary Cirrhosis Drug Price by Application (2017-2028)

7 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION

- 7.1 North America Primary Biliary Cirrhosis Drug Sales by Type (2017-2028)
- 7.2 North America Primary Biliary Cirrhosis Drug Sales by Application (2017-2028)
- 7.3 North America Primary Biliary Cirrhosis Drug Market Size by Country
- 7.3.1 North America Primary Biliary Cirrhosis Drug Sales in Volume by Country (2017-2028)
- 7.3.2 North America Primary Biliary Cirrhosis Drug Revenue by Country (2017-2028)
- 7.3.3 United States Market Size and Forecast (2017-2028)
- 7.3.4 Canada Market Size and Forecast (2017-2028)
- 7.3.5 Mexico Market Size and Forecast (2017-2028)

8 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION

- 8.1 Europe Primary Biliary Cirrhosis Drug Sales by Type (2017-2028)
- 8.2 Europe Primary Biliary Cirrhosis Drug Sales by Application (2017-2028)
- 8.3 Europe Primary Biliary Cirrhosis Drug Market Size by Country



- 8.3.1 Europe Primary Biliary Cirrhosis Drug Sales in Volume by Country (2017-2028)
- 8.3.2 Europe Primary Biliary Cirrhosis Drug Revenue by Country (2017-2028)
- 8.3.3 Germany Market Size and Forecast (2017-2028)
- 8.3.4 France Market Size and Forecast (2017-2028)
- 8.3.5 United Kingdom Market Size and Forecast (2017-2028)
- 8.3.6 Russia Market Size and Forecast (2017-2028)
- 8.3.7 Italy Market Size and Forecast (2017-2028)

9 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION

- 9.1 Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Type (2017-2028)
- 9.2 Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Application (2017-2028)
- 9.3 Asia-Pacific Primary Biliary Cirrhosis Drug Market Size by Region
- 9.3.1 Asia-Pacific Primary Biliary Cirrhosis Drug Sales in Volume by Region (2017-2028)
 - 9.3.2 Asia-Pacific Primary Biliary Cirrhosis Drug Revenue by Region (2017-2028)
 - 9.3.3 China Market Size and Forecast (2017-2028)
 - 9.3.4 Japan Market Size and Forecast (2017-2028)
 - 9.3.5 Korea Market Size and Forecast (2017-2028)
- 9.3.6 India Market Size and Forecast (2017-2028)
- 9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
- 9.3.8 Australia Market Size and Forecast (2017-2028)

10 SOUTH AMERICA BY REGION, BY TYPE, AND BY APPLICATION

- 10.1 South America Primary Biliary Cirrhosis Drug Sales by Type (2017-2028)
- 10.2 South America Primary Biliary Cirrhosis Drug Sales by Application (2017-2028)
- 10.3 South America Primary Biliary Cirrhosis Drug Market Size by Country
- 10.3.1 South America Primary Biliary Cirrhosis Drug Sales in Volume by Country (2017-2028)
 - 10.3.2 South America Primary Biliary Cirrhosis Drug Revenue by Country (2017-2028)
 - 10.3.3 Brazil Market Size and Forecast (2017-2028)
 - 10.3.4 Argentina Market Size and Forecast (2017-2028)

11 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION

- 11.1 Middle East & Africa Primary Biliary Cirrhosis Drug Sales by Type (2017-2028)
- 11.2 Middle East & Africa Primary Biliary Cirrhosis Drug Sales by Application (2017-2028)



- 11.3 Middle East & Africa Primary Biliary Cirrhosis Drug Market Size by Country
- 11.3.1 Middle East & Africa Primary Biliary Cirrhosis Drug Sales in Volume by Country (2017-2028)
- 11.3.2 Middle East & Africa Primary Biliary Cirrhosis Drug Revenue by Country (2017-2028)
 - 11.3.3 Turkey Market Size and Forecast (2017-2028)
 - 11.3.4 Egypt Market Size and Forecast (2017-2028)
 - 11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
- 11.3.6 South Africa Market Size and Forecast (2017-2028)

12 RAW MATERIAL AND INDUSTRY CHAIN

- 12.1 Raw Material of Primary Biliary Cirrhosis Drug and Key Manufacturers
- 12.2 Manufacturing Costs Percentage of Primary Biliary Cirrhosis Drug
- 12.3 Primary Biliary Cirrhosis Drug Production Process
- 12.4 Primary Biliary Cirrhosis Drug Industrial Chain

13 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS

- 13.1 Sales Channel
 - 13.1.1 Direct Marketing
 - 13.1.2 Indirect Marketing
- 13.2 Primary Biliary Cirrhosis Drug Typical Distributors
- 13.3 Primary Biliary Cirrhosis Drug Typical Customers

14 RESEARCH FINDINGS AND CONCLUSION

15 APPENDIX

- 15.1 Methodology
- 15.2 Research Process and Data Source
- 15.3 Disclaimer



List Of Tables

LIST OF TABLES

Table 1. Global Primary Biliary Cirrhosis Drug Revenue by Type, (USD Million), 2017 & 2021 & 2028

Table 2. Global Primary Biliary Cirrhosis Drug Revenue by Application, (USD Million), 2017 & 2021 & 2028

Table 3. AlbireoPharma Basic Information, Manufacturing Base and Competitors

Table 4. AlbireoPharma Major Business

Table 5. AlbireoPharma Primary Biliary Cirrhosis Drug Product and Services

Table 6. AlbireoPharma Primary Biliary Cirrhosis Drug Sales (K Pcs), Price (USD/Pcs),

Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 7. CymaBay Therapeutics, Inc. Basic Information, Manufacturing Base and Competitors

Table 8. CymaBay Therapeutics, Inc. Major Business

Table 9. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product and Services

Table 10. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 11. Dr. Falk Pharma GmbH Basic Information, Manufacturing Base and Competitors

Table 12. Dr. Falk Pharma GmbH Major Business

Table 13. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product and Services

Table 14. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales (K Pcs), Price

(USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 15. Enanta Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors

Table 16. Enanta Pharmaceuticals, Inc. Major Business

Table 17. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product and Services

Table 18. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 19. GlaxoSmithKline Plc Basic Information, Manufacturing Base and Competitors

Table 20. GlaxoSmithKline Plc Major Business

Table 21. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product and Services



- Table 22. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
- Table 23. Intercept Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
- Table 24. Intercept Pharmaceuticals, Inc. Major Business
- Table 25. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product and Services
- Table 26. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
- Table 27. Johnson & Johnson Basic Information, Manufacturing Base and Competitors Table 28. Johnson & Johnson Major Business
- Table 29. Johnson & Johnson Primary Biliary Cirrhosis Drug Product and Services
- Table 30. Johnson & Johnson Primary Biliary Cirrhosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
- Table 31. MediGene AG Basic Information, Manufacturing Base and Competitors
- Table 32. MediGene AG Major Business
- Table 33. MediGene AG Primary Biliary Cirrhosis Drug Product and Services
- Table 34. MediGene AG Primary Biliary Cirrhosis Drug Sales (K Pcs), Price (USD/Pcs),
- Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
- Table 35. NGM Biopharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
- Table 36. NGM Biopharmaceuticals, Inc. Major Business
- Table 37. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product and Services
- Table 38. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
- Table 39. Virobay Inc. Basic Information, Manufacturing Base and Competitors
- Table 40. Virobay Inc. Major Business
- Table 41. Virobay Inc. Primary Biliary Cirrhosis Drug Product and Services
- Table 42. Virobay Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Price (USD/Pcs),
- Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
- Table 43. Global Primary Biliary Cirrhosis Drug Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Pcs)
- Table 44. Global Primary Biliary Cirrhosis Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)



- Table 45. Market Position of Manufacturers in Primary Biliary Cirrhosis Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
- Table 46. Global Primary Biliary Cirrhosis Drug Production Capacity by Company, (K Pcs): 2020 VS 2021
- Table 47. Head Office and Primary Biliary Cirrhosis Drug Production Site of Key Manufacturer
- Table 48. Primary Biliary Cirrhosis Drug New Entrant and Capacity Expansion Plans
- Table 49. Primary Biliary Cirrhosis Drug Mergers & Acquisitions in the Past Five Years
- Table 50. Global Primary Biliary Cirrhosis Drug Sales by Region (2017-2022) & (K Pcs)
- Table 51. Global Primary Biliary Cirrhosis Drug Sales by Region (2023-2028) & (K Pcs)
- Table 52. Global Primary Biliary Cirrhosis Drug Revenue by Region (2017-2022) & (USD Million)
- Table 53. Global Primary Biliary Cirrhosis Drug Revenue by Region (2023-2028) & (USD Million)
- Table 54. Global Primary Biliary Cirrhosis Drug Sales by Type (2017-2022) & (K Pcs)
- Table 55. Global Primary Biliary Cirrhosis Drug Sales by Type (2023-2028) & (K Pcs)
- Table 56. Global Primary Biliary Cirrhosis Drug Revenue by Type (2017-2022) & (USD Million)
- Table 57. Global Primary Biliary Cirrhosis Drug Revenue by Type (2023-2028) & (USD Million)
- Table 58. Global Primary Biliary Cirrhosis Drug Price by Type (2017-2022) & (USD/Pcs)
- Table 59. Global Primary Biliary Cirrhosis Drug Price by Type (2023-2028) & (USD/Pcs)
- Table 60. Global Primary Biliary Cirrhosis Drug Sales by Application (2017-2022) & (K Pcs)
- Table 61. Global Primary Biliary Cirrhosis Drug Sales by Application (2023-2028) & (K Pcs)
- Table 62. Global Primary Biliary Cirrhosis Drug Revenue by Application (2017-2022) & (USD Million)
- Table 63. Global Primary Biliary Cirrhosis Drug Revenue by Application (2023-2028) & (USD Million)
- Table 64. Global Primary Biliary Cirrhosis Drug Price by Application (2017-2022) & (USD/Pcs)
- Table 65. Global Primary Biliary Cirrhosis Drug Price by Application (2023-2028) & (USD/Pcs)
- Table 66. North America Primary Biliary Cirrhosis Drug Sales by Country (2017-2022) & (K Pcs)
- Table 67. North America Primary Biliary Cirrhosis Drug Sales by Country (2023-2028) & (K Pcs)
- Table 68. North America Primary Biliary Cirrhosis Drug Revenue by Country



- (2017-2022) & (USD Million)
- Table 69. North America Primary Biliary Cirrhosis Drug Revenue by Country (2023-2028) & (USD Million)
- Table 70. North America Primary Biliary Cirrhosis Drug Sales by Type (2017-2022) & (K Pcs)
- Table 71. North America Primary Biliary Cirrhosis Drug Sales by Type (2023-2028) & (K Pcs)
- Table 72. North America Primary Biliary Cirrhosis Drug Sales by Application (2017-2022) & (K Pcs)
- Table 73. North America Primary Biliary Cirrhosis Drug Sales by Application (2023-2028) & (K Pcs)
- Table 74. Europe Primary Biliary Cirrhosis Drug Sales by Country (2017-2022) & (K Pcs)
- Table 75. Europe Primary Biliary Cirrhosis Drug Sales by Country (2023-2028) & (K Pcs)
- Table 76. Europe Primary Biliary Cirrhosis Drug Revenue by Country (2017-2022) & (USD Million)
- Table 77. Europe Primary Biliary Cirrhosis Drug Revenue by Country (2023-2028) & (USD Million)
- Table 78. Europe Primary Biliary Cirrhosis Drug Sales by Type (2017-2022) & (K Pcs)
- Table 79. Europe Primary Biliary Cirrhosis Drug Sales by Type (2023-2028) & (K Pcs)
- Table 80. Europe Primary Biliary Cirrhosis Drug Sales by Application (2017-2022) & (K Pcs)
- Table 81. Europe Primary Biliary Cirrhosis Drug Sales by Application (2023-2028) & (K Pcs)
- Table 82. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Region (2017-2022) & (K Pcs)
- Table 83. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Region (2023-2028) & (K Pcs)
- Table 84. Asia-Pacific Primary Biliary Cirrhosis Drug Revenue by Region (2017-2022) & (USD Million)
- Table 85. Asia-Pacific Primary Biliary Cirrhosis Drug Revenue by Region (2023-2028) & (USD Million)
- Table 86. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Type (2017-2022) & (K Pcs)
- Table 87. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Type (2023-2028) & (K Pcs)
- Table 88. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Application (2017-2022) & (K Pcs)



Table 89. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Application (2023-2028) & (K Pcs)

Table 90. South America Primary Biliary Cirrhosis Drug Sales by Country (2017-2022) & (K Pcs)

Table 91. South America Primary Biliary Cirrhosis Drug Sales by Country (2023-2028) & (K Pcs)

Table 92. South America Primary Biliary Cirrhosis Drug Revenue by Country (2017-2022) & (USD Million)

Table 93. South America Primary Biliary Cirrhosis Drug Revenue by Country (2023-2028) & (USD Million)

Table 94. South America Primary Biliary Cirrhosis Drug Sales by Type (2017-2022) & (K Pcs)

Table 95. South America Primary Biliary Cirrhosis Drug Sales by Type (2023-2028) & (K Pcs)

Table 96. South America Primary Biliary Cirrhosis Drug Sales by Application (2017-2022) & (K Pcs)

Table 97. South America Primary Biliary Cirrhosis Drug Sales by Application (2023-2028) & (K Pcs)

Table 98. Middle East & Africa Primary Biliary Cirrhosis Drug Sales by Region (2017-2022) & (K Pcs)

Table 99. Middle East & Africa Primary Biliary Cirrhosis Drug Sales by Region (2023-2028) & (K Pcs)

Table 100. Middle East & Africa Primary Biliary Cirrhosis Drug Revenue by Region (2017-2022) & (USD Million)

Table 101. Middle East & Africa Primary Biliary Cirrhosis Drug Revenue by Region (2023-2028) & (USD Million)

Table 102. Middle East & Africa Primary Biliary Cirrhosis Drug Sales by Type (2017-2022) & (K Pcs)

Table 103. Middle East & Africa Primary Biliary Cirrhosis Drug Sales by Type (2023-2028) & (K Pcs)

Table 104. Middle East & Africa Primary Biliary Cirrhosis Drug Sales by Application (2017-2022) & (K Pcs)

Table 105. Middle East & Africa Primary Biliary Cirrhosis Drug Sales by Application (2023-2028) & (K Pcs)

Table 106. Primary Biliary Cirrhosis Drug Raw Material

Table 107. Key Manufacturers of Primary Biliary Cirrhosis Drug Raw Materials

Table 108. Direct Channel Pros & Cons

Table 109. Indirect Channel Pros & Cons

Table 110. Primary Biliary Cirrhosis Drug Typical Distributors



Table 111. Primary Biliary Cirrhosis Drug Typical Customers



List Of Figures

LIST OF FIGURES

Figure 1. Primary Biliary Cirrhosis Drug Picture

Figure 2. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type in 2021

Figure 3. Budesonide

Figure 4. FFP-104

Figure 5. GSK-2330672

Figure 6. MBX-8025

Figure 7. NGM-282

Figure 8. Others

Figure 9. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application in 2021

Figure 10. Clinic

Figure 11. Hospital

Figure 12. Others

Figure 13. Global Primary Biliary Cirrhosis Drug Revenue, (USD Million) & (K Pcs):

2017 & 2021 & 2028

Figure 14. Global Primary Biliary Cirrhosis Drug Revenue and Forecast (2017-2028) & (USD Million)

Figure 15. Global Primary Biliary Cirrhosis Drug Sales (2017-2028) & (K Pcs)

Figure 16. Global Primary Biliary Cirrhosis Drug Price (2017-2028) & (USD/Pcs)

Figure 17. Global Primary Biliary Cirrhosis Drug Production Capacity (2017-2028) & (K Pcs)

Figure 18. Global Primary Biliary Cirrhosis Drug Production Capacity by Geographic

Region: 2022 VS 2028

Figure 19. Primary Biliary Cirrhosis Drug Market Drivers

Figure 20. Primary Biliary Cirrhosis Drug Market Restraints

Figure 21. Primary Biliary Cirrhosis Drug Market Trends

Figure 22. Global Primary Biliary Cirrhosis Drug Sales Market Share by Manufacturer in 2021

Figure 23. Global Primary Biliary Cirrhosis Drug Revenue Market Share by

Manufacturer in 2021

Figure 24. Primary Biliary Cirrhosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021

Figure 25. Top 3 Primary Biliary Cirrhosis Drug Manufacturer (Revenue) Market Share in 2021

Figure 26. Top 6 Primary Biliary Cirrhosis Drug Manufacturer (Revenue) Market Share



in 2021

Figure 27. Global Primary Biliary Cirrhosis Drug Sales Market Share by Region (2017-2028)

Figure 28. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2017-2028)

Figure 29. North America Primary Biliary Cirrhosis Drug Revenue (2017-2028) & (USD Million)

Figure 30. Europe Primary Biliary Cirrhosis Drug Revenue (2017-2028) & (USD Million)

Figure 31. Asia-Pacific Primary Biliary Cirrhosis Drug Revenue (2017-2028) & (USD Million)

Figure 32. South America Primary Biliary Cirrhosis Drug Revenue (2017-2028) & (USD Million)

Figure 33. Middle East & Africa Primary Biliary Cirrhosis Drug Revenue (2017-2028) & (USD Million)

Figure 34. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type (2017-2028)

Figure 35. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2017-2028)

Figure 36. Global Primary Biliary Cirrhosis Drug Price by Type (2017-2028) & (USD/Pcs)

Figure 37. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2017-2028)

Figure 38. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2017-2028)

Figure 39. Global Primary Biliary Cirrhosis Drug Price by Application (2017-2028) & (USD/Pcs)

Figure 40. North America Primary Biliary Cirrhosis Drug Sales Market Share by Type (2017-2028)

Figure 41. North America Primary Biliary Cirrhosis Drug Sales Market Share by Application (2017-2028)

Figure 42. North America Primary Biliary Cirrhosis Drug Sales Market Share by Country (2017-2028)

Figure 43. North America Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2017-2028)

Figure 44. United States Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 45. Canada Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 46. Mexico Primary Biliary Cirrhosis Drug Revenue and Growth Rate



(2017-2028) & (USD Million)

Figure 47. Europe Primary Biliary Cirrhosis Drug Sales Market Share by Type (2017-2028)

Figure 48. Europe Primary Biliary Cirrhosis Drug Sales Market Share by Application (2017-2028)

Figure 49. Europe Primary Biliary Cirrhosis Drug Sales Market Share by Country (2017-2028)

Figure 50. Europe Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2017-2028)

Figure 51. Germany Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. France Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. United Kingdom Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. Russia Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. Italy Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share by Region (2017-2028)

Figure 57. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share by Application (2017-2028)

Figure 58. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share by Region (2017-2028)

Figure 59. Asia-Pacific Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2017-2028)

Figure 60. China Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. Japan Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. Korea Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. India Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. Southeast Asia Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. Australia Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)



Figure 66. South America Primary Biliary Cirrhosis Drug Sales Market Share by Type (2017-2028)

Figure 67. South America Primary Biliary Cirrhosis Drug Sales Market Share by Application (2017-2028)

Figure 68. South America Primary Biliary Cirrhosis Drug Sales Market Share by Country (2017-2028)

Figure 69. South America Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2017-2028)

Figure 70. Brazil Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. Argentina Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 72. Middle East & Africa Primary Biliary Cirrhosis Drug Sales Market Share by Type (2017-2028)

Figure 73. Middle East & Africa Primary Biliary Cirrhosis Drug Sales Market Share by Application (2017-2028)

Figure 74. Middle East & Africa Primary Biliary Cirrhosis Drug Sales Market Share by Region (2017-2028)

Figure 75. Middle East & Africa Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2017-2028)

Figure 76. Turkey Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 77. Egypt Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 78. Saudi Arabia Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 79. South Africa Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. Manufacturing Cost Structure Analysis of Primary Biliary Cirrhosis Drug in 2021

Figure 81. Manufacturing Process Analysis of Primary Biliary Cirrhosis Drug

Figure 82. Primary Biliary Cirrhosis Drug Industrial Chain

Figure 83. Sales Channel: Direct Channel vs Indirect Channel

Figure 84. Methodology

Figure 85. Research Process and Data Source



I would like to order

Product name: Global Primary Biliary Cirrhosis Drug Market 2022 by Manufacturers, Regions, Type and

Application, Forecast to 2028

Product link: https://marketpublishers.com/r/G94E68129628EN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G94E68129628EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to $+44\ 20\ 7900\ 3970$



